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Abstract: The field of IL-17 biology has received much attention over the last decade owing to the
pathogenic role of this cytokine in psoriasis and other autoinflammatory disorders and the successful
implementation of IL-17-targeting therapies in patients suffering from these diseases. IL-17-mediated
pathologies are contrasted by the important host beneficial effects of this cytokine. IL-17 is essential
for regulating microbial colonization in barrier tissues. Rare congenital defects in the IL-17 pathway
exemplify the relevance of IL-17 in protective immunity against the opportunistic fungal pathogen C.
albicans. However, more recently, evidence is accumulating that IL-17 can also provide protection against
fungi other than C. albicans. Importantly, protective IL-17 responses directed against commensal fungi
can, under certain conditions, promote inflammation with detrimental consequences for the host, thereby
assigning fungi a new role as disease-promoting factors apart from their role as potential infectious agents.
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Abstract: The field of IL-17 biology has received much attention over the last decade owing to
the pathogenic role of this cytokine in psoriasis and other autoinflammatory disorders and the
successful implementation of IL-17-targeting therapies in patients suffering from these diseases.
IL-17-mediated pathologies are contrasted by the important host beneficial effects of this cytokine.
IL-17 is essential for regulating microbial colonization in barrier tissues. Rare congenital defects in
the IL-17 pathway exemplify the relevance of IL-17 in protective immunity against the opportunistic
fungal pathogen C. albicans. However, more recently, evidence is accumulating that IL-17 can also
provide protection against fungi other thanC. albicans. Importantly, protective IL-17 responses directed
against commensal fungi can, under certain conditions, promote inflammation with detrimental
consequences for the host, thereby assigning fungi a new role as disease-promoting factors apart from
their role as potential infectious agents.
Keywords: Interleukin-17; fungal pathogens; fungal commensals; C. albicans; host protection;
immunopathology
1. IL-17 Immunity in Health and Disease
Interleukin (IL)-17 is an ancient and therefore well-conserved cytokine, although it was discovered
rather late compared to other key cytokines [1]. Since its first description, and in particular over the
last 15 years, IL-17 has been intensely studied in the context of human and mouse immunology as well
as in very distant organisms such as the pacific oyster, sea urchin or sea squirt [2–4]. The IL-17 cytokine
family consists of six members (IL-17A through IL-17F), among which IL-17A and IL-17F are the best
characterized cytokines [5]. This is attributed to their high sequence homology and close functional
relationship. In this review, we focus on IL-17A and IL-17F and use the term IL-17 interchangeably for
both cytokines.
IL-17 has gained much attention for its implication in autoinflammatory disorders.
Dysregulation of the IL-17 pathway is associated with the development of diseases such as psoriasis
and rheumatoid arthritis. Three therapeutic antibodies targeting IL-17A or its receptor and another
three antibodies targeting one of the two subunits of the IL-17-regulating factor IL-23 have been
brought to market over the past four years [6]. These antibodies demonstrate surprisingly rapid
efficacy against moderate to severe forms of plaque psoriasis with short treatment periods. In addition,
recent trials suggest that patients suffering from other diseases such as ankylosing spondylitis and
psoriatic arthritis would benefit from IL-17 blockade [7].
Importantly however, IL-17 confers not only detrimental effects to the host, but this cytokine is also
critical for maintaining an equilibrium between the host and the microbiota in barrier tissues during
homeostasis. In the gut, IL-17 is produced by a subset of CD4+ T cells, called Th17 cells, as well as by
innate lymphoid cells in response to commensal microbes and in turn prevents microbial dysbiosis by
a regulating effector mechanism in the epithelium that prevents the overgrowth of microbes. As a
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consequence, the use of anti-IL-17 therapy may come at the price of disrupting microbial homeostasis,
potentially resulting in opportunistic infections. This is exemplified by the adverse effect of anti-IL-17
and IL-17R treatment for patients with Crohn’s disease [8,9]. These results are backed up with studies
in mice documenting a protective role of IL-17 in controlling the gut microbiota [10,11]. Of note,
in contrast to biological therapies targeting IL-17, those targeting IL-23 showed beneficial effects in
patients suffering from intestinal inflammatory disease, indicating that some actions of IL-23 may be
independent of IL-17 immunity.
One of the very few adverse effects of IL-17-targeting therapies in psoriasis patients described so
far has been the occurrence of fungal infections, particularly superficial infections caused by Candida, in
a small proportion of the treated patients [12]. This does not come as a surprise given the essential role
of IL-17 in protection from this fungus, which is now well accepted based on patient and mouse studies.
2. IL-17 Immunity against C. albicans
Rare genetic defects in the IL-17 pathway indicated a non-redundant role of IL-17 in protective
immunity against fungal infections, especially those caused by Candida albicans and rarely non-albicans
species of Candida. Early on, it was observed that patients suffering from chronic mucocutaneous
candidiasis (CMC) exhibit reduced production of IL-17 and IL-22 cytokines [13]. Later on, rare genetic
defects were identified in patients suffering from familial forms of CMC with symptoms manifesting
in the oral mucosa, the skin and the nails [14]. Mutations were identified in a small number of selected
genes, in particular those encoding for IL-17F, the IL-17 receptor subunits A and C, the signaling
adaptor ACT1 and the IL-17-instructing transcription factor RORγt [15–18]. By far, the most common
mutations associated with CMC are STAT1 GOF (gain of function) and STAT3 LOF (loss of function)
alleles [19–24]. In addition, mutations in the genes coding for DOCK8 [25,26] and for the adaptor
molecule CARD9, which links innate fungal recognition to Th17 induction are also associated with
increased susceptibility to CMC [27–31]. CARD9 is the only gene also associated with invasive forms
of fungal diseases, including deep-seated dermatophytosis, fungal encephalitis and extrapulmonary
aspergillosis, indicating that this factor regulates functions in antifungal immunity beyond the epithelial
barrier [32]. In the cases of CNS candidiasis and extrapulmonary aspergillosis, the defect in CARD9
was mapped to the lack of neutrophil recruitment [28,33].
Of all forms of superficial candidiasis, vulvovaginal candidiasis (VVC) is the most common
disease, affecting not only immunocompromised but also otherwise healthy women [34]. One
of the most prominent predisposing factors for VVC is dysbiosis induced by antibiotics [35].
Primary immunodeficiency patients with defects in the IL-17 pathway frequently display symptoms of
VVC in combination with those affecting the oropharynx, the skin and/or the nails, indicating a role of
IL-17 in the prevention of this disease. However, in contrast to mucocutaneous candidiasis, the exact
role of IL-17 in VVC remains controversial [36,37]. The immunopathogenesis of VVC is now believed
to be rather a consequence of neutrophil dysfunction due to heparin-sulfate-mediated inhibition [38].
The relevance of IL-17-mediated antifungal defense in the oro-gastrointestinal tract and the
skin was investigated in detail using experimental models of superficial Candida infection in mice.
Studies employing the models of oropharyngeal candidiasis (OPC) or epicutaneous candidiasis
greatly improved our current knowledge about the cellular and molecular mechanisms underlying
IL-17-mediated immunity against Candida in barrier tissues.
3. Mechanisms of IL-17 Induction and Function
As a consequence of C. albicans being a commensal in humans, Candida-specific memory cell
populations can be found in all human individuals, which are preferentially polarized towards the
Th17 subset [39–41]. Likewise, a selective type 17 immune response is triggered in mice that are
experimentally infected with C. albicans in the oral cavity without concurrent induction of IFN-γ or
IL-4/-5/-13 [42,43]. The antifungal Th17 response in mice also generates memory [42] that augments
antifungal protection upon re-infection via the same route [44,45]. Of note, the C. albicans-specific Th17
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response is highly conserved and independent of genetic variations, which exist within the species
of C. albicans and which entail differences in the virulence between individual fungal isolates [46,47].
Using low-virulent strains of C. albicans in experimental OPC has allowed the establishment of a model
of persistent infection that closely mimics the situation of fungal commensalism in humans [46,47].
However, the original and still most commonly used mouse models of superficial candidiasis
employ the highly virulent strain SC5314 or derivatives thereof. This strain triggers a very rapid
inflammatory response in mice that are not usually colonized with C. albicans under specific
pathogen-free conditions. The acute and very strong activation of the immune system in response to
primary exposure to the fungus results in rapid clearance of the fungus within only a few days [43,48].
The natural resistance of mice to C. albicans is strictly dependent on a functional IL-17 pathway [43,
48]. The rapid infection kinetics with strain SC5314 preclude a contribution of Th17 to fungal control.
It was thus suggested that innate immune cells participate in the production of IL-17. Indeed, γδ T
cells, innate lymphoid cells (ILCs) and a population of αβ T cells (also called “natural Th17 cells” by
some) have been identified in the oral mucosa as an important source of IL-17 shortly after the onset
of experimental OPC [49,50]. Of these three subsets, the identity of the αβ T cells remains the most
poorly characterized, and their putative relationship to tissue-resident memory cells remains to be
clarified. The three IL-17-producing innate cell populations act in a complementary and partially
redundant manner in the oral mucosa to ensure rapid production of IL-17 at the onset of infection
for rapid fungal control. The lack of one or two of these populations, as is the case in TCRγδ- or
RAG-deficient animals, results in a less severe phenotype than those observed in the absence of the
entire lymphoid compartment (e.g., in Rag-/- Il2rg-/- mice) or the full IL-17 signaling pathway (e.g., in
Il17ra-/- mice) [48]. In the skin, dermal γδ T cells rather than αβ T cells or ILCs are the main producers
of innate IL-17 in response to experimental infection with C. albicans [51], consistent with the numerical
and functional dominance of γδ T cells in this organ. Neutrophils were shown to serve as a source of
IL-17 in the context of ocular mold infections [52]. However, no evidence exists that they contribute
to IL-17 production during oropharyngeal or epicutaneous candidiasis. The role of ILCs and innate
lymphocytes in antifungal defense in humans who are constantly exposed to C. albicans has not been
assessed so far, but it can be speculated that they also contribute to protection in barrier tissues.
IL-17 production by innate and adaptive immunity is instructed by polarizing cytokines, in
particular IL-23, IL-1 and IL-6. Production of these cytokines in the infected tissue has been studied in
depth during murine oropharyngeal and epicutaneous candidiasis with strain SC5314. A lack of any
of these factors (or combinations of these factors) impairs IL-17 induction and protective antifungal
immunity [43,45,48–50]. In the oral mucosa, tissue-resident Langerin+ dendritic cells (DCs) occupy a
unique position as coordinators of the acute IL-17 response by co-producing all three IL-17-inducing
factors in response to C. albicans [50]. In addition, IL-1 is also provided by the epithelium in response
to the fungal peptide toxin candidalysin [53], which is strongly expressed during filamentation of
virulent strains of C. albicans. Candidalysin causes damage in host cells and consequently facilitatesthe
release of alarmins including IL-1α from the damaged cells [54].
Avirulent strains of C. albicans have been shown to induce an attenuated and delayed host response
in experimentally infected mice [46,47], while the adaptive immune response is activated regularly
and indistinguishably in response to both, high- and avirulent strains. This indicates that the fungal
determinants of pathogenicity that induce a rapid inflammatory response to high-virulent strains are
distinct from more conserved molecular patterns that instruct Th17 immunity for the surveillance of
persistently colonizing fungus [46]. The mechanism of Th17 cell priming in response to avirulent strains
of C. albicans, which induce only limited levels of the polarizing cytokines IL-1, IL-6 and IL-23 [46,47],
remains to be determined.
The type of DCs driving innate vs. adaptive antifungal IL-17 immunity differ between different
sites of infection. While Langerhans cells play a critical role at the onset of infection in the context
of oropharyngeal candidiasis [50], they are redundant for the activation of adaptive Th17 immunity
in this model, where infiltrating myeloid cells adopt the role of antigen-presenting cells [55]. In the
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skin however, Langerhans cells contribute to the priming of the adaptive antifungal response to C.
albicans by providing IL-6, but instead they are not required for innate immunity in this tissue [56].
Importantly, research from the epicutaneous candidiasis model in mice has linked neuronal sensitization
to antifungal immunity by demonstrating that TRPV1+ neurons in the skin sense C. albicans and instruct
dermal CD301b+ DCs to produce IL-23, which in turn drives IL-17 production by dermal γδ T cells [51].
This is consistent with a growing body of literature on the regulation of immunological processes by
peripheral neurons in homeostasis and disease [57]. Resident commensal microbiota have also been
shown to regulate local IL-17 production and prevent fungal infection. Corynebacterium mastidis, a
component of the microbiota of the ocular surface in mice and humans, stimulates tissue-resident γδ
T cells to produce IL-17, which in turn is necessary to confer protection against invasive C. albicans
infection of the eye [58].
While research on IL-17 in recent years has mainly focused on its cellular source, we still know
relatively little about the host-protective effector functions of this cytokine contributing to fungal
control. Neutrophils have been linked to type-17 immunity and IL-17 target genes are associated with
neutrophil trafficking [59,60]. Indeed, neutrophils have a key role for protective antifungal immunity
in the oral mucosa as they prevent dissemination of virulent C. albicans strains [61,62]. However,
abrogation of IL-17 signaling during OPC does not affect neutrophil recruitment to the site of infection,
nor does it impair the neutrophil antifungal activity [62]. Moreover, IL-17 induction during OPC with
avirulent C. albicans strains is not sufficient for neutrophil recruitment into the infected tissue [46].
This indicates that neutrophils take action independently of IL-17, or even act upstream of local IL-17
production by secreting IL-17-instructing cytokines during the acute phase of OPC [50].
IL-17 exerts its effector function primarily by targeting non-hematopoietic cells in barrier tissue
including epithelial cells and fibroblasts [63]. Indeed, deletion of the IL-17RA subunit from keratin
13-expressing oral epithelial cells phenocopied the susceptibility of IL-17RA full knockouts to OPC [64].
IL-17 induces the production of antimicrobial peptides (AMPs) by those cells, including S100A8 and
S100A9 (together forming the heterodimeric complex calprotectin), lipocalin 2 and β-defensins [43].
These compounds have been shown to display direct fungicidal activity by permeabilizing the fungal
cell wall [65] or by dampening fungal growth via sequestration of essential metal ions [65–68]. In
addition to their antimicrobial activity, AMPs can also act as chemoattractants. In contrast to calprotectin
and lipocalin 2, which are also highly expressed by activated neutrophils, the expression of β-defensins
is largely restricted to epithelial cells [69]. β-defensin-3-deficiency was linked to impaired fungal
control during murine OPC [64], while β-defensin-1 was reported to modulate host immunity with
impaired neutrophil recruitment and reduced expression of inflammatory cytokines including IL-17,
and consequently increased susceptibility to infection in the absence of β-defensin-1 [70]. The defect
of AMP-deficient mice in antifungal immunity is not as rigorous as in mice lacking the entire IL-17
pathway, suggesting a certain degree of redundancy between different AMPs. In line with this, lipocalin
2, which is one of the most strongly upregulated factors in response to IL-17 induction in the oral
mucosa, is dispensable for protective immunity [71] and the phenotype of β-defensin-3-deficient mice
was not reproducible in our studies (Kirchner, Sparber and LeibundGut-Landmann, unpublished).
Thus, the identification of the relevant effector molecules mediating IL-17-dependent immunity to
C. albicans infection awaits further investigation.
4. IL-17 in Antifungal Immunity beyond Candida
The vast majority of all studies on the protective effects of IL-17 immunity against fungal infections
has been focused on C. albicans. However, the mammalian host is exposed to diverse other fungi,
including airborne fungi that we inhale and fungi to which our skin is exposed. Studies in mice
have revealed a potential role of IL-17 in the defense against many of these fungi. Protection from
Pneumocystis carinii [72] and the dimorphic fungi Histoplasma capsulatum [73,74] and Blastomyces
dermatitis [75] has been shown to depend on a functional IL-17 pathway. Reminiscent of what is known
from the IL-17 response to C. albicans, experimental infection of mice with B. dermatitis induces an
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acute response characterized by rapid production of IL-17 and GM-CSF by tissue-resident γδ T cells
via a mechanism that involves IL-1α secretion from lung epithelial cells [76]. One of the most clinically
relevant airborne fungal pathogens is Aspergillus fumigatus. In an experimental aspergillosis model,
fungal killing was shown to depend on Dectin-1-mediated induction of IL-17 [77]. The relevance
of IL-17 in lung immunity against A. fumigatus gained support from studies reporting an increased
frequency of Th17 cells in the lung tissue of COPD and cystic fibrosis patients, who frequently suffer
from pulmonary aspergillosis [78,79]. However, whether the fungus-specific Th17 cells in these patients
mediate fungal control or, alternatively, may contribute to lung pathology that is associated with COPD
remains an open question. Dysregulated Th17 responses have recently been linked to the induction of
immunopathology and were associated with disease severity in asthma [80,81].
IL-17 immunity has also gained attention for providing protection from fungi on the skin.
Various fungi beyond Candida can cause different forms of dermatomycosis. Dermatophytes are the
most frequent skin fungal pathogens encountered in human and veterinary dermatology [82,83]. Early
observations in human patients suggested a protective role of IL-17 against this class of fungi [84–86].
More recently, two independent studies in mice further underlined the crucial role of IL-17 for
antifungal immunity against dermatophytes. Experimental infection of the skin with Microsporum
canis resulted in the induction of a fungus-specific Th17 response in the skin draining lymph nodes.
Analyzing the host response to dermatophytes in IL-17-deficient animals revealed that IL-17 not
only limits dermatophyte growth on the skin, but also antagonizes a non-protective Th1 response
against the fungus, which in the absence of IL-17 resulted in excessive skin inflammation and fungal
overgrowth [87]. A similar protective role for Th17 has been demonstrated against the dermatophyte
Trichophyton benhamiae [88]. While this most recent study confirmed the critical role of Th17 cells in
protection from dermatophytosis, it reported a synergistic instead of an antagonistic role of IL-17- and
IFN-γ-producing T cells to facilitate optimal fungal clearance [88]. The discrepancy between the two
studies may be explained by differences in the two fungal genera, the mouse background and microbial
status and/or details in the experimental protocol including the preparation of the mice for infection.
However, the common feature remains the host protective role of IL-17 against dermatophytes.
The most prominent fungal commensal organisms colonizing the skin are those of the genus
Malassezia [89]. Besides their role as commensals with potential benefits for the host during homeostasis,
Malassezia spp. have also been associated with several common skin disorders including pityriasis
versicolor and dandruff as well as more severe inflammatory skin pathologies such as atopic dermatitis
(AD) in humans [90] and dermatitis and otitis externa in animals, most frequently in dogs [91].
The mechanism by which Malassezia promotes pathology remains largely unclear. A recent study
from our lab established an experimental model to study the host response to Malassezia in the skin
in vivo and thereby revealed a dichotomous role of IL-17 in antifungal immunity as well as in skin
inflammation [92]. Topical application of Malassezia spp. onto murine skin resulted in rapid and
selective induction of IL-17 in the skin by γδ T cells, αβ T cells and to a lesser extent ILCs. In addition,
infected animals mounted an adaptive immune response to the fungus in the skin-draining lymph
nodes characterized by IL-17- and IL-22-producing Th17 cells, without concomitant Th1 or Th2
priming. Reminiscent of the IL-17 response induced during acute experimental OPC [50], skin-resident
Langerhans cells orchestrated the IL-17 response during Malassezia skin infection by providing
IL-23 [92]. Importantly, IL-17 deficiency resulted in impaired fungal control [92]. Under AD-like
conditions, which were mimicked by barrier disruption of the epidermis, the IL-23/IL-17 response to
Malassezia spp. promoted skin pathology [92], supporting the hypothesis that the skin commensal
yeast exacerbates disease severity in AD. The relevance of these data obtained in mice is supported by
the observation that the frequency of Malassezia-specific Th17 cells was increased in the blood of AD
patients compared to healthy individuals [92,93]. Together, these studies provide ample evidence for a
role of IL-17-mediated immunity against fungi beyond C. albicans that confers host protection, but may
also promote immunopathology under certain conditions.
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5. Concluding Remarks
IL-17 emerged as a key player in antifungal immunity in barrier tissues and many labs have
contributed in recent years to the current understanding of the cellular and molecular mechanisms of
IL-17 regulation by fungi and effector functions against fungi. The relevance of IL-17 in controlling
fungal growth is most prominent for C. albicans as evidenced by the predominant occurrence of CMC
in patients with genetic defects in the IL-17 pathway. Numerous indications that IL-17 contributes to
protection from fungi other than C. albicans have been obtained from studies with experimental models
of infection. However, it remains less clear to what extent IL-17 is essential for controlling these fungi
in humans. This may in part be due to compensatory mechanisms of protection that gain importance if
the IL-17 pathway is impaired. The relevance of IL-17 for fungal control may also have been off the
grid for fungi, which do not cause symptoms of classical infectious disease if uncontrolled.
C. albicans occupies a unique position as the major inducer of human Th17 responses in healthy
individuals [94]. Remarkably, Th17 cells directed against other fungi are induced by cross-reactivity to
C. albicans [94]. Such cross-reactive Th17 cells also include those with pathogenic potential, e.g., the
potential to drive airway inflammation during allergic bronchopulmonary aspergillosis [94]. This notion
is supported by a recent study in mice where Th17 responses directed against intestinal colonization
with C. albicans exacerbate susceptibility to allergic airway inflammation in an experimental model
of asthma [95]. Also, Th17 cells directed against other fungi such as Malassezia bear the potential
to promote immunopathology [92]. Therefore, type 17 immunity directed against commensal fungi
provides protection beyond the fungus against which it is originally primed. However, it also acts
as a potential risk factor for inflammatory diseases. Understanding the delicate balance between
IL-17-mediated protection and pathology in more detail is essential for all aspirations to therapeutically
modulate the IL-17 pathway.
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